BioSpace News Archive

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced a $100 million non-dilutive financing transaction with Abingworth to fund the Phase 3 development program for seladelpar in primary biliary cholangitis, including the Phase 3 RESPONSE clinical trial.

Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, will release financial results for the second quarter ended June 30, 2021, after market close on Monday, August 16, 2021 at 4:30 p.m. Eastern time.

Mustang Bio, Inc. today announced that the European Medicines Agency (“EMA”) has granted Priority Medicines (“PRIME”) designation to MB-107, its lentiviral gene therapy for the treatment of X-linked severe combined immunodeficiency.

Universe Pharmaceuticals INC today announced its unaudited financial results for the first six months of fiscal year 2021 ended March 31, 2021.

Happiness Biotech Group Limited today announced its financial results for the fiscal year ended March 31, 2021 .

Avidity Biosciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) cleared the company to proceed with the Phase 1/2 MARINA™ clinical trial of AOC 1001 in adults with myotonic dystrophy type 1 (DM1).

Preclinical neuroscience company Delix Therapeutics (the “Company”), today announced the appointment of Dr. Brigitte Robertson as Chief Medical Officer.

First-of-its-kind initiative provides patients in India with access to remote opinions and consultations, using technology from India-based telemedicine provider iCliniq

Vaxart, Inc. announced today that the U.S. Food and Drug Administration has cleared Vaxart’s Investigational New Drug application for an S-only oral tablet SARS-CoV-2 vaccine candidate.

Carrick Therapeutics today announced a clinical collaboration with Roche to evaluate a novel combination of Carrick’s samuraciclib and Roche’s giredestrant in CDK4/6i resistant HR+, HER2- metastatic breast cancer.